An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
Status:
RECRUITING
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
An Open-Label, Non-Randomized Study to Assess the Safety and Efficacy of Leniolisib in Japanese Patients With Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Followed By an Open-Label Long-Term Extension.
For the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
Phase:
PHASE3
Details
Lead Sponsor:
Pharming Technologies B.V.
Collaborators:
Axial Biotech, Inc CMIC Co, Ltd. Japan Laboratory Corporation of America